Correlation Between Milestone Pharmaceuticals and Inhibikase Therapeutics
Can any of the company-specific risk be diversified away by investing in both Milestone Pharmaceuticals and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Milestone Pharmaceuticals and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Milestone Pharmaceuticals and Inhibikase Therapeutics, you can compare the effects of market volatilities on Milestone Pharmaceuticals and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Milestone Pharmaceuticals with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Milestone Pharmaceuticals and Inhibikase Therapeutics.
Diversification Opportunities for Milestone Pharmaceuticals and Inhibikase Therapeutics
0.53 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Milestone and Inhibikase is 0.53. Overlapping area represents the amount of risk that can be diversified away by holding Milestone Pharmaceuticals and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and Milestone Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Milestone Pharmaceuticals are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of Milestone Pharmaceuticals i.e., Milestone Pharmaceuticals and Inhibikase Therapeutics go up and down completely randomly.
Pair Corralation between Milestone Pharmaceuticals and Inhibikase Therapeutics
Given the investment horizon of 90 days Milestone Pharmaceuticals is expected to generate 1.08 times more return on investment than Inhibikase Therapeutics. However, Milestone Pharmaceuticals is 1.08 times more volatile than Inhibikase Therapeutics. It trades about 0.19 of its potential returns per unit of risk. Inhibikase Therapeutics is currently generating about -0.18 per unit of risk. If you would invest 172.00 in Milestone Pharmaceuticals on October 20, 2024 and sell it today you would earn a total of 26.00 from holding Milestone Pharmaceuticals or generate 15.12% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Milestone Pharmaceuticals vs. Inhibikase Therapeutics
Performance |
| Timeline |
| Milestone Pharmaceuticals |
| Inhibikase Therapeutics |
Milestone Pharmaceuticals and Inhibikase Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Milestone Pharmaceuticals and Inhibikase Therapeutics
The main advantage of trading using opposite Milestone Pharmaceuticals and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Milestone Pharmaceuticals position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.The idea behind Milestone Pharmaceuticals and Inhibikase Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
| Inhibikase Therapeutics vs. DiaMedica Therapeutics | Inhibikase Therapeutics vs. Milestone Pharmaceuticals | Inhibikase Therapeutics vs. Seres Therapeutics | Inhibikase Therapeutics vs. Oncolytics Biotech |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Complementary Tools
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |